Drugs / CAR-M-C-MET
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07553793 | May 2026 → Dec 2028 expected | malignant pancreatic neoplasm | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-M-c-MET | “Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy.” PMID 39643883 ↗ Dec 2024 |
| Action | Deplete | “CAR-M-c-MET cells demonstrated highly specific binding to pancreatic cancer cells and exhibited more phagocytosis and killing abilities than the pro-inflammatory polarized...” PMID 39643883 ↗ Dec 2024 |
| Modality | Cell therapy | “CAR-M-C-MET) is a novel cellular therapy for these patients.” NCT07553793 ↗ |
| Route | Other | “The final cell product is cryopreserved and later administered via intraperitoneal infusion.” NCT07553793 ↗ |